Your browser doesn't support javascript.
loading
A novel strategy for treating oncogene-mutated tumors by targeting tumor microenvironment and synergistically enhancing anti-PD-1 immunotherapy.
Liu, Yingqiang; Tong, Linjiang; Zhang, Mengge; Zhang, Qi; Liu, Qiupei; Feng, Fang; Li, Yan; Lai, Mengzhen; Tang, Haotian; Chen, Yi; Geng, Meiyu; Duan, Wenhu; Ding, Jian; Xie, Hua.
Afiliación
  • Liu Y; Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P. R. China.
  • Tong L; Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P. R. China.
  • Zhang M; Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P. R. China.
  • Zhang Q; University of Chinese Academy of Sciences, Beijing, P. R. China.
  • Liu Q; Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P. R. China.
  • Feng F; University of Chinese Academy of Sciences, Beijing, P. R. China.
  • Li Y; Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P. R. China.
  • Lai M; Department of Chemical and Environmental Engineering, University of Nottingham Ningbo China, Ningbo, Zhejiang, P. R. China.
  • Tang H; Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P. R. China.
  • Chen Y; Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P. R. China.
  • Geng M; Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P. R. China.
  • Duan W; Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P. R. China.
  • Ding J; Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, Guangdong, P. R. China.
  • Xie H; Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P. R. China.
Cancer Commun (Lond) ; 44(3): 438-442, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38335159
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Microambiente Tumoral / Neoplasias Límite: Humans Idioma: En Revista: Cancer Commun (Lond) Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Microambiente Tumoral / Neoplasias Límite: Humans Idioma: En Revista: Cancer Commun (Lond) Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos